



PATENT

Our Docket: P-BU 5149

1614
COPY OF PAPERS
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Sperandio and Bredesen)
Serial No.: 10/079,929)
Filed: February 19, 2002)
For: MODULATORS OF PARAPTOSIS)
AND RELATED METHODS)

Examiner: Not yet assigned

Group Art Unit: 1614

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 19, 2002.

By Astrid R. Spain
Astrid R. Spain, Reg. No. 47,956

Commissioner for Patents
Washington, D.C. 20231

July 19, 2002

Date of Signature

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-0370.

Respectfully submitted,

RECEIVED

JUL 26 2002

Date: July 19, 2002

Astrid R. Spain

Astrid R. Spain

Registration No.: 47,956

Telephone: (858) 535-9001

Facsimile: (858) 535-8949

TECH CENTER 1600/2900

Campbell & Flores LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601

Form PTO 1449 US Department of Commerce Patents and Trademark Office JUL 24 2002	ATTY DOCKET NO: P-BU 5149	SERIAL NO. 10/079,929
	APPLICANT: Sperandio and Bredesen	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 19, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

		Dal Canto and Gurney, "Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis," <u>American Journal of Pathology</u> 145:1271-1279 (1994)
		Hongo et al., "Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor," <u>Cancer Research</u> 58:2477-2484 (1998)
		Liu et al., "Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells," <u>Cancer Research</u> 58:570-576 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

JUL 26 2002

TECH CENTER 1600/2900

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-BU 5149	SERIAL NO. 10/079,929
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Sperandio and Bredesen	
	FILING DATE: February 19, 2002	GROUP: 1614

		Liu et al., "Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)," <u>Cell</u> 75:59-72 (1993)
		Plymate et al., "Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis," <u>Endocrine</u> 7:119-124 (1997)
		Sperandio et al., "An alternative, nonapoptotic form of programmed cell death," <u>Proc. Natl. Acad. Sci. USA</u> 97:14376-14381 (2000)
		Tennant et al., "Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium," <u>J. Clin. Endocrinol. Metab.</u> 81:3774-3782 (1996)
		Turmaine et al., "Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease," <u>Proc. Natl. Acad. Sci. USA</u> 97:8093-8097 (2000)

RECEIVED

 COPY OF PAPERS
 ORIGINALLY FILED

JUL 26 2002

TECH CENTER 1600.2

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.